Key facts
- Dynocardia’s last known valuation is $12.5M (Jan 2021).
- It has raised $8.3M across 4 recorded rounds; the latest was Seed Round ($1.2M) in Mar 2025.
- Notable investors include US National Science Foundation, National Institutes of Health, NextCorps Luminate, Mayo Clinic Platform, 3DEXPERIENCE Lab — 11 tracked in total.
- Dynocardia has filed 12 Form Ds with the SEC since 2019, most recently Dec 2025 ($4.8M sold to 47 investors).
- Status: Privately Held (backing).
Investors
11+- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Dynocardia
Funding rounds
4 roundsAbout Dynocardia
Developer of a wearable blood pressure monitoring device designed to accurately and continuously measure blood pressure. The company's technology facilitates a wearable optomechanical sensor that uses a non-invasive method to measure blood pressure continuously and accurately, enabling users to accurately measure respiration, heart rate, and cardiac hemodynamic parameters.
- Sector
- Healthcare
- HQ
- Lowell, MA, United States
- Founded
- 2015
- Employees
- 12
- Website
- dynocardia.care/
- Ownership
- Privately Held (backing)
Dynocardia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dynocardia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dynocardia in its N-PORT filings yet. We sweep new filings monthly.